Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. [electronic resource]
Producer: 20060821Description: 3789-98 p. digitalISSN:- 1527-7755
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- genetics
- Carcinoma, Squamous Cell -- drug therapy
- Chemotherapy, Adjuvant
- Critical Pathways
- DNA-Binding Proteins -- genetics
- Dose Fractionation, Radiation
- Esophageal Neoplasms -- drug therapy
- Esophagectomy -- methods
- Esophagogastric Junction
- Female
- Fluorouracil -- administration & dosage
- Genes, MDR
- Genotype
- Humans
- Male
- Methylenetetrahydrofolate Reductase (NADPH2) -- genetics
- Middle Aged
- Neoadjuvant Therapy -- methods
- Odds Ratio
- Platinum Compounds -- administration & dosage
- Polymorphism, Single Nucleotide
- Predictive Value of Tests
- Prognosis
- Proportional Hazards Models
- Radiotherapy, Adjuvant
- Retrospective Studies
- Risk Assessment
- Stomach Neoplasms -- drug therapy
- Survival Analysis
- Taxoids -- administration & dosage
- Treatment Outcome
- X-ray Repair Cross Complementing Protein 1
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.